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Racial differences in symptom management
approaches among persons with radiographic
knee osteoarthritis
Shibing Yang1*, Rachel Jawahar1, Timothy E McAlindon2, Charles B Eaton3,4 and Kate L Lapane1
Abstract
Background: The extent to which racial differences exist in use of treatments for osteoarthritis (OA) is
debatable. The purpose of this study was to describe the differences between African Americans (AA) and
Caucasian Americans (CA) in using treatment approaches to manage symptoms among individuals with
radiographic-confirmed knee OA.
Methods: A cross-sectional study was conducted. Using data from the Osteoarthritis Initiative, we identified 508 AA
and 2,075 CA with radiographic tibiofemoral OA in at least one knee. Trained interviewers asked questions relating
to current OA treatments including seven CAM therapy categories—alternative medical systems, mind-body
interventions, manipulation and body-based methods, energy therapies, and three types of biologically based
therapies, as well as conventional medications. We categorized participants as: conventional medication only users,
CAM only users, users of both and users of neither. Multinomial logistic regression models adjusting for
sociodemographics and clinical/functional factors provided estimates of the association between race and
treatment use.
Results: Overall, 16.5% of AA and 24.2% of CA exclusively used CAM to treat OA, 25.0% of AA and 23.8% of CA
used CAM in conjunction with conventional medications, and 24.8% of AA and 14.6% of CA exclusively used
conventional medications. After control for sociodemographic and clinical factors, AA were less likely than CA to
use CAM therapies alone (adjusted odds ratio (OR) of using CAM alone relative to no CAM or conventional
treatments: 0.68, 95% confidence interval (CI): 0.48–0.96) or with conventional medications (adjusted OR relative to
no CAM or conventional treatments: 0.59, 95%CI: 0.42–0.83). However, no differences in use of conventional
medications alone were observed after adjustment of covariates.
Conclusion: CAM use is common among people with knee OA, but is less likely to be used by AA relative to CA.
For effective CAM therapies, targeted outreach to underserved populations including education about benefits of
various CAM treatments and providing accessible care may attenuate observed disparities in effective CAM use by
race.
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Background
Osteoarthritis (OA) of the knee is the most common type
of OA and 12–16% of Americans older than 60 years suf-
fer from this ailment [1,2]. Knee OA has detrimental
effects on individuals’ physical function and quality of life
and is the leading cause of disability among non-
institutionalized adults in the United States [3,4].
Advanced OA accounts for the majority of knee joint re-
placement surgeries among Medicare recipients [5].
Current guidelines recommend treatment of OA with
both pharmacological and non-pharmacological methods,
consisting of pain management using acetaminophen or
non-steroidal anti-inflammatory drugs (NSAIDs), com-
bined with patient education, exercise, and/or weight loss
[6]. Although not part of the guidelines, complementary
and alternative medicine (CAM) is increasingly used
among persons with OA, possibly due to inadequate heal-
ing effects or more adverse effects from conventional
medications [7-9], or due to cultural influences which
make some race/ethnicity groups favor CAM [10,11]. In-
deed, arthritis is the most commonly cited reason for
using CAM [12].
The extent to which racial differences exist in use of
treatments for OA is debatable. Studies of racial differ-
ences in use of CAM therapies among persons with
arthritis have been inconsistent [13,14]. In a population-
based sample with self-reported arthritis, Caucasian
Americans (CA) were 50% more likely than African
Americans (AA) to have used CAM [13], while another
study with arthritis patients found that AA were more
likely to report CAM use than CA (89.1% versus 77.7%)
[14]. While understanding differences in CAM use by
race is hampered by the lack of systematic CAM defini-
tions, as well as details regarding specific CAM treat-
ments, studies have consistently shown that AA are less
likely than CA to use biologically based supplements
[13]. Different explanations for racial differences in
CAM use have been posited. AA may have developed
healing traditions using herbs and other substances
owing to lack of access to even rudimentary medical
care [15]. It is also possible that differences in disease se-
verity may have accounted for racial differences in the
use of CAM therapies [16,17]. Similar to studies on
CAM use, studies on racial differences in use of conven-
tional medications for OA also yielded inconsistent
results, with some studies [18,19], but not all [17],
reporting greater use of conventional medications
among CA relative to AA.
The Osteoarthritis Initiative (OAI) is a multi-center,
prospective observational study, aimed to examine the
natural history of knee OA and to identify risk factors
for incidence and progression of knee OA [20]. The
availability of the OAI data offers a unique opportunity
to evaluate racial differences in OA treatments. First,
unlike previous reports [13,14,18,19], the OAI offers a
population with radiographic confirmation of OA. Sec-
ond, the detailed assessments of knee specific pain, qual-
ity of life and functioning indicators permit the
adjustment for disease severity. Using baseline data from
OAI, we sought to describe the differences between CA
and AA in using treatment approaches to manage symp-
toms of knee OA. As our secondary objective, we further
identified correlates of therapy choice among CA and
AA from sociodemographic and clinical characteristics.
Methods
The study protocol was approved by the Institutional
Review Boards of Virginia Commonwealth University
and the Memorial Hospital of Rhode Island. Because
publicly-available data were used for this study, the Insti-
tutional Review Boards waived the need for documenta-
tion of informed consent.
Study subjects
We used publicly available data from the OAI (#AllCli-
nical00, V0.2.2). From February 2004 to May 2006, four
study sites (i.e., Baltimore, MD; Columbus, OH; Pitts-
burgh, PA; and Pawtucket, RI.) recruited 4,796 partici-
pants either with established knee OA or at high risk for
developing knee OA [20]. Participants were followed for
up to four years.
Participants had a standing posterior-anterior radio-
graphic examination on both knees at enrollment. Using
the “fixed-flexion” knee radiography protocol, knees
were flexed to 20–30° and feet were internally rotated
10° [21]. An Osteoarthritis Research Society Inter-
national (OARSI) atlas osteophyte grade greater than or
equal to I (equivalent to Kellgren and Lawrence grade ≥
2) [22] was considered evidence of radiographic knee
OA. We included participants with radiographic-
confirmed OA in at least one knee. Since only 38 and 58
persons self-identified as Hispanics and “other race”, re-
spectively, we were unable to include them in further
race/ethnicity specific analyses. The final analytic sample
included 508 participants who self-identified as AA and
2,075 who self-identified as CA.
Treatment approaches
The National Center for Complementary and Alternative
Medicine defined seven broad categories as CAM use in-
cluding: 1) alternative medical systems (acupuncture, acu-
pressure, homeopathy and others); 2) mind-body
interventions (yoga/Tai Chi/Chi Gong/pilates, spiritual ac-
tivities, relaxation therapy, meditation, deep breathing or
visualization); 3) manipulation and body-based methods
(chiropractic and massage); 4) energy therapies (copper
bracelets or magnets); 5) biologically based topical therap-
ies (rubs, lotions, liniments, creams or oils, capsaicin); 6)
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biologically based diet; and 7) biologically based supple-
ments (herbals, glucosamine, chondroitin, vitamins/miner-
als, methylsulfonylmethane, S-adenosylmethionine) [23].
In OAI, a series of questions specifically asked about
whether CAM approaches for arthritis or joint pain were
used in the past 30 days (for methylsulfonylmethane and
S-adenosylmethionine), past 6 months (for glucosamine
and chondroitin), or past 12 months (for all other CAM
therapies) and how frequently these therapies were used.
A participant was considered a CAM user, if he/she self-
reported using glucosamine and chondroitin “every day or
nearly every day”, taking methylsulfonylmethane and S-
adenosylmethionine “more than half days of the past
month”, or “currently” using any of other types of CAM
therapies.
Participants were asked “During the past 30 days, have
you used any of the following medications for joint pain
or arthritis on most days? By most days, we mean more
than half the days of the month.”, with separate ques-
tions for: acetaminophen, over-the-counter NSAIDs,
prescription NSAIDs, prescription COX-2 inhibitors,
doxycycline, prescription “strong pain” medications such
as opioids, and knee injections of corticosteroid or hya-
luronic acid. Self-report use of any of the abovemen-
tioned medications was considered using conventional
medication.
To analyze CAM and conventional medication use
simultaneously, we categorized use of treatment
approaches into four groups, i.e., using only CAM, using
only conventional medications, concomitantly using
both and using neither (reference group).
Potential correlates
Besides race, we considered other sociodemographic
and clinical characteristics which may potentially influ-
ence using treatment approaches. Trained interviewers
administered surveys which collected self-reported in-
formation on sociodemographic characteristics, includ-
ing age, gender, education, income, marital status and
insurance coverage for prescription medicines. Partici-
pants were asked to recall the highest grade that they
had completed, with options including high school
graduate, some college degree or technical school and
college graduate or above. Income was measured with
personal family income for the last year, including all
sources such as wages, salaries, social security and retire-
ment benefits. Options for this question were: ≤ $50,000,
$50,000–100,000 and > $100,000. Participants’ marital
status was categorized as either being married/partnered
or being single (i.e., widowed, divorced, separated or
never married). Participants were considered having
prescription insurance coverage if they gave positive
answers to the question “Do you have any health
insurance plan that pays for all or part of the cost of
prescription medicines?”
OAI used Knee injury and Outcomes in Osteoarthritis
Score (KOOS) [24] to measure the severity of OA-related
knee symptoms. There are five domains for KOOS scale,
i.e., Pain, Symptoms, Knee Related Quality of Life, Func-
tion in Daily Living and Function in Sport and Recre-
ational Activities. For each domain, a summary score
ranging from 0 to 100 was calculated. Score 0 indicates
extreme symptoms and 100 indicates no symptoms.
Symptom-related multi-joint OA was measured to
capture the effect of generalized OA on using treatment
approaches. We considered symptom-related multi-joint
OA present if participants had OA symptoms in any of
the three joints: hand, hip and lower back. We also con-
sidered the history of having a knee injury that limited
ability to walk for at least two days, and history of hav-
ing knee surgery that included arthroscopy, ligament re-
pair or meniscectomy.
The 12-item Short-Form Health Survey (SF-12) pro-
vided an assessment of general health status [25].
Answers to the 12 questions were combined, scored,
and weighted to create physical health score and mental
health score. The scores also range from 0 to 100, with
greater value indicating better health status. Body mass
index (BMI) was calculated from measured height and
weight [weight (kg)/height (m2)]. Participants with a
BMI greater than 30 kg/m2 were considered obese [26].
Statistical analysis
Our first goal was to evaluate the extent to which treat-
ment approaches differed by race. To do this, we first
evaluated the distribution of the outcome variable
(CAM and conventional use simultaneously) and then
deconstructed the composite measure to look at the spe-
cific distributions of conventional medications and CAM
approaches by race. Because we were concerned about
confounding by sociodemographic and clinical charac-
teristics, we developed a multivariable multinomial logis-
tic regression model to estimate the association between
race and treatment use [27]. We first visually inspected
the distribution of sociodemographic and clinical charac-
teristics for AA and CA. We considered variables with
absolute differences of greater than 5% as potential con-
founders [28]. Before modeling we also evaluated the po-
tential for multicollinearity amongst the possible
correlate variables under study by checking correlations
between the covariates. Because KOOS Pain subscale
was highly correlated with subscales of Symptoms, Func-
tion in Daily Living and Function in Sport and Recre-
ational Activities (correlation coefficients were over
0.85), only Pain and Quality of Life subscales were
included in the modeling.
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An iterative approach (but not computer-driven) was
used to build the model. We first entered each potential
confounder separately into the model with the term for
race (coded as 1 for AA, 0 for CA). From these models,
we selected the factor that altered the effect for race the
most and retained this variable for the next iteration.
We then considered additional candidate variables. We
proceeded until no additional variables induced material
change (at least 10%) to our estimate of effect. To assure
ourselves that additional groups of variables combined
did not introduce confounding, we also developed an
adjusted model which included a cluster of sociodemo-
graphic variables and then added a cluster of clinical
characteristics. The models produced three odds ratios
(ORs) and corresponding 95% confidence intervals (CIs)
to compare AA to CA: 1) odds of using CAM only rela-
tive to use of neither; 2) odds of using conventional
medications only relative to use of neither; and 3) odds
of using both CAM and conventional medications rela-
tive to use of neither.
To describe the correlates of treatment use patterns
among AA and CA, we developed separate multinomial
logistic regression models by race. Correlates considered
included sociodemographic and clinical characteristics.
Although initially evaluated, medication insurance cover-
age, marital status, SF-12 mental health score, KOOS
Function in Daily Living and KOOS Function in Sport
and Recreational Activities were not associated with
treatment use in CA or AA. Thus, we did not include
these factors in the final models. To provide more clin-
ically meaningful results for the KOOS subscales and
SF-12 physical health score, we provided ORs of one
standard deviation change in each of these variables.
The number of AA in our analytic sample was substan-
tially smaller than that of CA (508 versus 2,075) and as
such, some correlates may not have reached statistical
significance owing to limited sample size. Recognizing
the limitations of p-values in this situation, we consid-
ered statistically significant correlates among CA whose
ORs were identical or qualitatively similar to the ORs
among AA as noteworthy.
Results
Table 1 shows the sociodemographic and clinical charac-
teristics between AA and CA with radiographic-
confirmed OA of the knee. The gender distribution
varied with more AA being women than CA. AA were
younger, less likely to be married or in partnered rela-
tionships, had attained less education, and had lower in-
come than CA. There were a higher proportion of
persons being obese among AA relative to CA. Com-
pared to AA, CA reported better outcomes on five
domains of KOOS scale.
Shown in Table 2 are the specific CAM therapies used
by AA and CA. Biologically based supplement use was
more common among CA (35.4%) relative to AA
(17.9%). Glucosamine and chondroitin use were the
most commonly reported CAM supplement use among
both CA and AA, but CA were three times as likely as
AA to use them. The opposite pattern was observed for
use of biologically based topical agents with AA (23.2%)
reporting use more than CA (10.7%). Six percent of CA
reported using chiropractic or massage, but it was rarely
used by AA (1.4%). AA were more likely than CA to re-
port relaxation therapies or spiritual activities (12.4%
versus 4.7%). Table 3 shows the use of conventional
medications as current treatments of OA by race. Over-
the-counter NSAIDs were the most commonly used
drugs to treat OA in both groups, and its use was more
prevalent among AA (28.0%) than among CA (19.5%).
AA were also more likely than CA to use acetaminophen
(17.9% versus 9.5%).
Table 4 shows the association between race and treat-
ment approaches used for OA. Overall, 16.5% of AA and
24.2% of CA exclusively used CAM to treat OA, 25.0%
of AA and 23.8% of CA used CAM in conjunction with
conventional medications, and 24.8% of AA and 14.6%
of CA exclusively used conventional medications. How-
ever, after adjustment for sociodemographic and clinical
characteristics, AA were less likely to use CAM either
alone or in combination with conventional medications.
While in the unadjusted analysis AA were more likely
than CA to exclusively use conventional medications,
this was explained by confounding by disease severity.
The correlates of treatment use were identified for AA
(Table 5) and CA (Table 6). Among AA, those aged
65 years or older tended to report more use of treat-
ments relative to younger participants. Women were
more likely to use CAM alone or in combination with
conventional medications than men. An association was
also found between higher incomes and using CAM.
Among CA, women were more likely than men to use
all treatment approaches. Income greater than $100,000
was associated with concomitantly using both types of
treatments. Radiographic evidence of severe knee joint
damage was correlated with using all treatment
approaches. Symptoms measures, including knee pain,
knee-related quality of life, symptoms-related multi-joint
OA and general physical health, were also correlated
with using CAM or conventional medications.
Discussion
In a large population of participants with radiographic-
confirmed OA of the knee, overall CAM use is preva-
lent, but less so among AA. After adjustment for socio-
demographic and clinical characteristics, CAM use was
less common among AA than CA, while no differences
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in use of conventional medications remained. In addition
to differences in the overall prevalence of use, we
observed differences in the specific types of CAM used
by race. The cross-sectional data used in this study do
not permit any evaluation of the effectiveness of CAM
approaches on symptom management in knee OA, nor
do we suggest these data are documenting health dispar-
ities. Rather, the unique data collected as part of the
OAI (symptoms, severity, radiographic confirmation,
detailed CAM assessments) are useful to further our
understanding of racial differences in CAM use.
Our finding that AA are less likely to use CAM
therapies than CA is consistent with some previous
studies [13,29,30]. Our work extends similar reports
based on the general US population [29,30], as well as
persons with self-reported arthritis [13], to a popula-
tion with radiographically confirmed knee OA. Our
work is not consistent with other reports [14,17], how-
ever. Comparing results of CAM use across studies is
challenging because researchers often use different
definitions of CAM. The detailed questionnaire of the
OAI related to CAM permitted us to place our study
into context with the extant literature. We confirmed
that indeed the discrepancies between our findings and
results from several other studies may primarily be
due to different definitions of CAM use. Katz and Lee
reported that CAM was more common among AA
than CA, which was driven by biologically based diets
to treat OA (75.2% of AA used biologically based diet
relative to 60.9% of CA) [14]. In our study, however,
we found only 1% of AA and CA used this method.
Another study reporting greater CAM use among AA
relative to CA did not include massage and chiroprac-
tic service as CAM therapy [17]. Consistent with other
studies [13], we found that CA used more biologically
based supplements, especially glucosamine and chon-
droitin, and chiropractic services relative to AA. Also
consistent with the literature [14,16,17], we found that
AA used more spiritual and religious activities and
topical agents relative to CA.
Table 1 Characteristics of participants with radiographic-confirmed knee osteoarthritis by race (N=2583)
Characteristic African Americans Caucasian Americans
(n = 508) (n = 2075)
percentage
Age (years): ≥ 65 30.5 46.4
Women 70.9 55.0
Education
≤ High school 31.0 15.3
≥ Some college 69.0 84.7
Income ($)
≤ 50,000 66.5 36.9
50,000–100,000 25.9 38.2
>100,000 7.6 24.8
Married/partnered 37.2 72.7
Insurance covers prescriptions 84.6 87.5
Kellgren-Lawrence Grade
2 33.5 31.5
3 49.4 47.2
4 17.1 21.3
Symptom-related multi-joint osteoarthritis 68.5 68.9
History of knee injury or surgery 46.9 56.3
Obesity 66.1 38.5
mean (standard deviation)
KOOS Pain 61.6 (23.0) 78.3 (18.1)
KOOS Symptoms 63.7 (21.6) 78.6 (17.6)
KOOS Quality of Life 51.2 (23.4) 65.5 (22.1)
KOOS Function in Daily Life 67.9 (22.3) 84.8 (16.2)
KOOS Function in Sports and Recreational Activities 52.8 (24.3) 69.9 (21.5)
SF-12 Mental Health Score 52.1 (10.1) 54.3 (7.6)
SF-12 Physical Health Score 42.3 (10.8) 48.9 (8.7)
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We found that, without adjusting sociodemographic
and clinical characteristics, AA were nearly twice as likely
as CA to use conventional medications. Greater scrutiny
of the actual medications revealed that the largest differ-
ences were observed with over-the-counter medications
such as acetaminophen and NSAIDs, whereas CA
reported greater use of prescription COX-2 inhibitors
relative to AA (9.3% versus 5.7%). This is consistent with
previous work [18, 19], as well as in equal access health
systems requiring minimal co-payments for medications
[31]. In our study and in others [31,32], AA experienced
more severe pain and other symptoms than CA despite
having less severe radiographic evidence of disease. Never-
theless, after controlling for clinical factors, we found
similar use of conventional medications by race. Yet, des-
pite these adjustments, the finding that AA were less likely
than CA to use CAM either exclusively or with conven-
tional medications persisted.
While the reasons for racial differences in CAM use are
likely multifactorial, one possible reason for the differ-
ences we observed may be differential access to care by
race. Compared to AA, CA have better access to health
care services [33]. In equal access systems, no racial differ-
ences in overall frequency of OA related physician visits
or visits to rheumatologists were observed among veter-
ans with OA [31]. But in our study, CA were more likely
to have reported X-ray examination of their knees prior to
study entry relative to AA which may in turn have led to
more treatment using CAM. Moreover, relative to AA,
CA did appear to report more CAM approaches that
required access to the medical system (practitioners), e.g.,
chiropractic service. Further, in our study, AA had less fa-
vorable socioeconomic positioning (as measured by mari-
tal status, education and income) relative to CA. CAM
therapies are not covered by insurance. Indeed, among
AA, those with income over $50,000 were more likely to
use CAM therapies. Some of CAM approaches, such as
glucosamine [34] and acupuncture [35], have been shown
beneficial in relieving symptoms among OA patients.
However, as found in our study, both glucosamine and
Table 2 CAM use among participants with radiographic-confirmed knee osteoarthritis by race (N=2583)
Category * African Americans Caucasian Americans
(n = 508) (n = 2075)
percentage
Alternative medical systems 0.2 1.4
Acupuncture/ Acupressure 0.2 1.0
Ayurveda/biofeedback/energy healing/ hypnosis/naturopathy/Homeopathy 0.0 0.7
Mind-body interventions 13.8 9.7
Yoga/Tai Chi/Chi Gong/pilates 2.8 6.5
Relaxation therapy, meditation, deep breathing or visualization, spiritual activities 12.4 4.7
Manipulation and body-based methods 1.4 6.1
Energy therapies 3.7 3.5
Biologically based therapies: topical agents 23.2 10.7
Biologically based therapies: supplements 17.9 35.4
Glucosamine (nearly every day) 11.6 31.7
Chondroitin (nearly every day) 10.4 29.0
Vitamins/minerals 5.5 6.4
Methylsulfonylmethane (MSM) 3.9 6.3
Herbs 3.0 1.2
S-adenosylmethionine (SAME) 0.4 0.5
Biologically based therapies: diet 1.2 1.0
*As defined by the National Center for Complementary and Alternative Medicine.
Table 3 Conventional medication use among participants
with radiographic-confirmed knee osteoarthritis by race
(N= 2583)
Category African Americans Caucasian Americans
(n = 508) (n = 2075)
percentage
Acetaminophen 17.9 9.5
Over-the-counter NSAIDs 28.0 19.5
Prescription NSAIDs 10.2 7.0
COX-2 inhibitors 5.7 9.3
Opioids 3.9 2.6
Knee injection 4.7 3.5
Corticosteroid 4.1 2.4
Hyaluronic Acid 0.6 1.3
Doxycycline 0.6 0.3
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acupuncture were less frequently used among AA than
among CA. If further studies confirm the effectiveness in
delaying disease progression and ameliorating symptoms,
CAM therapies should be promoted and made accessible
to minority populations.
We found an association between age and CAM use
among AA, but not CA. Older AA were more likely than
those younger than 65 years of age to report use of CAM,
conventional medications or both, but this age effect was
not found among CA. Our findings align with studies that
report older AA hold more positive views about CAM
and use CAM more frequently than younger AA [15,36].
The differential effects of age on using conventional medi-
cation may be explained by different perceptions between
AA and CA on side effects of conventional medications
[31]. AA are less likely than CA to recognize any risk asso-
ciated with over-the-counter and prescription NSAIDs
[37]. Indeed, AA are less likely than CA to report that
their doctors have discussed NSAID-related gastrointes-
tinal problems [37]. Given that NSAIDs constitute the ma-
jority of conventional medications used for treating OA,
this could explain why there was no increase in
Table 4 Association between race and using treatment approaches among participants with radiographic-confirmed
knee osteoarthritis (N = 2583)
Treatment Use African Americans Caucasian Americans Crude Sociodemographic
Characteristics
Adjusted †
Sociodemographic
and Clinical
Characteristics
Adjusted {
(n = 508) (n = 2075)
percentage Odds ratios of African Americans relative to Caucasian Americans
(95% confidence intervals)
CAM Only 16.5 24.2 0.76 0.77 0.68
(0.57–1.01) (0.56–1.06) (0.48–0.96)
Conventional Medication Only 24.8 14.6 1.89 1.57 0.96
(1.45–2.46) (1.16–2.15) (0.68–1.35)
Both 25.0 23.8 1.17 1.11 0.59
(0.91–1.51) (0.83–1.49) (0.42–0.83)
Neither 33.7 37.5 Reference group of outcome variable
† Adjusted sociodemographics include age, gender, education, income, marital status and medication insurance coverage.
{ Besides sociodemographic variables, full model also adjusted KOOS Pain and Quality of Life subscales, Kellgren-Lawrence Grade, history of knee injury or
surgery, symptom-related multi-joint osteoarthritis, SF-12 mental health scale, SF-12 physical health scale and obesity status.
Table 5 Correlates† of treatment approaches among African Americans with radiographic-confirmed knee
osteoarthritis (N = 508)
CAM Only (N = 84) Conventional Medication Only (N= 126) Both (N= 127)
Odds ratios (95% confidence intervals)
Age≥ 65 years 1.74 (0.90–3.37) 1.44 (0.80–2.61) 2.03 (1.09–3.77)
Women 1.79 (0.91–3.53) 1.02 (0.57–1.80) 1.82 (0.96–3.43)
Education
≥ Some college 1.02 (0.50–2.07) 0.96 (0.53–1.76) 1.55 (0.81–2.96)
High school or less 1.0 1.0 1.0
Income ($)
>100,000 2.23 (0.72–6.92) 0.47 (0.12–1.86) 2.82 (1.01–7.84)
50,000–100,000 2.28 (1.15–4.50) 0.95 (0.50–1.82) 0.83 (0.41–1.68)
≤ 50,000 1.0 1.0 1.0
KOOS Pain{ 0.78 (0.50–1.23) 0.65 (0.44–0.97) 0.54 (0.35–0.81)
KOOS Quality of Life{ 0.81 (0.52–1.25) 0.71 (0.49–1.05) 0.66 (0.44–1.00)
Kellgren-Lawrence grade: 0.94 (0.41–2.17) 0.91 (0.44–1.90) 1.08 (0.52–2.26)
4 versus 2 or 3
Symptom-related multi-joint osteoarthritis 1.06 (0.56–2.00) 1.04 (0.59–1.85) 1.56 (0.83–2.93)
History of knee injury/surgery 0.93 (0.51–1.68) 0.64 (0.37–1.09) 0.77 (0.44–1.35)
SF-12 Physical Health Score{ 0.72 (0.48–1.09) 0.77 (0.53–1.10) 0.72 (0.49–1.04)
Obesity 1.05 (0.56–1.96) 1.18 (0.67–2.06) 0.71 (0.39–1.30)
† Reference group includes participants who did not report use of CAM or conventional medications for osteoarthritis treatment.
{ Odds ratios are per one standard deviation (SD) change in SF-12 Physical Health Score (SD= 10.8) and KOOS subscales of Pain (SD= 23.0) and Quality of life
(SD = 23.4).
Yang et al. BMC Complementary and Alternative Medicine 2012, 12:86 Page 7 of 10
http://www.biomedcentral.com/1472-6882/12/86
conventional medication use among older CA compared
to younger CA.
Our study has several limitations. First, we could only
evaluate CAM practices in AA and CA. While others re-
port that Hispanics and Asian Americans are more likely
to use CAM therapies [14, 38], we were unable to evaluate
this in our data. Second, it would have been preferable to
identify correlates for each type of CAM treatment, but
we were unable to because of inadequate sample size.
Such analyses would have been more useful for under-
standing potential areas for intervention [39]. Lastly, only
self-reported information on CAM and conventional
medication therapies was available. Use of treatments was
based on a 30-day or 6-month recall. As such, it is pos-
sible that participants did not accurately report the use of
treatments. Further, persons with OA of the knee are
prone to recall bias of treatments [40]. Nevertheless, if
present, the misclassification of participants to treatment
approaches is likely to have been non-differential which
would have diluted any observed associations.
Conclusions
We observed racial differences in use of CAM therapies
either alone or in conjunction with conventional medica-
tions, but similar use of exclusive conventional medica-
tions by race. Understanding the extent to which the
observed differences represent overuse of CAM among
CA with OA of the knee, or underuse of CAM among AA
with OA of the knee is a critical next step. With respect to
correlates of use of treatment approaches, older AA are
more enthusiastic about trying both CAM and conven-
tional medications than younger AA. Socioeconomic dis-
advantages of AA may explain their less use of CAM
compared to CA. More studies are needed to explore the
benefits and risks of both conventional and CAM therap-
ies among the underserved populations.
Abbreviations
AA: African Americans; BMI: body mass index; CA: Caucasian Americans;
CAM: complementary and alternative medicine; CI: confidence interval;
KOOS: Knee injury and Outcomes in Osteoarthritis Score; NSAIDs: non-
steroidal anti-inflammatory drugs; OA: osteoarthritis; OAI: Osteoarthritis
Initiative; OARSI: Osteoarthritis Research Society International; OR: odds ratio;
SF-12: 12-item Short-Form Health Survey.
Competing interests
The Osteoarthritis Initiative (OAI) is a public-private partnership comprised of
five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-
2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch
of the Department of Health and Human Services, and conducted by the
OAI Study Investigators. Private funding partners include Pfizer, Inc.; Novartis
Pharmaceuticals Corporation; Merck Research Laboratories; and
GlaxoSmithKline. Private sector funding for the OAI is managed by the
Foundation for the National Institutes of Health.
Dr. Eaton has received grants from and has served as a consultant to Pfizer.
Dr. Lapane has served as a consultant to Pfizer and Ortho McNeil Johnson.
Table 6 Correlates† of treatment approaches among Caucasian Americans with radiographic-confirmed knee
osteoarthritis (N = 2075)
CAM Only Conventional Medication Only Both
(N = 502) (N = 303) (N = 493)
Odds ratios (95% confidence intervals)
Age≥ 65 years 1.07 (0.82–1.38) 0.98 (0.72–1.34) 1.10 (0.83–1.45)
Women 1.67 (1.30–2.15) 1.54 (1.14–2.08) 2.36 (1.79–3.11)
Education
≥ Some college 1.81 (1.23–2.67) 0.89 (0.60–1.32) 1.25 (0.85–1.83)
≤High school or less 1.0 1.0 1.0
Income ($)
>100,000 0.86 (0.61–1.22) 1.15 (0.76–1.75) 1.47 (1.02–2.12)
50,000–100,000 0.83 (0.62–1.11) 0.97 (0.68–1.37) 0.97 (0.70–1.33)
≤ 50,000 1.0 1.0 1.0
KOOS Pain{ 1.09 (0.90–1.33) 0.78 (0.63–0.97) 0.75 (0.62–0.91)
KOOS Quality of Life{ 0.69 (0.57–0.83) 0.87 (0.69–1.09) 0.59 (0.48–0.73)
Kellgren-Lawrence grade: 1.62 (1.18–2.24) 1.45 (1.00–2.11) 1.90 (1.37–2.65)
4 versus 2 or 3
Symptom-related multi-joint osteoarthritis 1.43 (1.11–1.85) 1.67 (1.21–2.30) 2.43 (1.79–3.29)
History of knee injury/surgery 1.40 (1.09–1.81) 1.27 (0.93–1.72) 1.06 (0.80–1.39)
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